Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
Conditions : Metastatic Pancreatic Cancer Interventions : Drug: XNW28012 Sponsors : Evopoint Biosciences Inc. Not yet recruiting
Read the full article2d agoen
Comments
Sign in to join the conversation.
No comments yet. Be the first.